166 related articles for article (PubMed ID: 34088773)
41. Toward Single-Time-Point Image-Based Dosimetry of
Brosch-Lenz J; Delker A; Völter F; Unterrainer LM; Kaiser L; Bartenstein P; Ziegler S; Rahmim A; Uribe C; Böning G
J Nucl Med; 2023 May; 64(5):767-774. PubMed ID: 36657980
[TBL] [Abstract][Full Text] [Related]
42. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
43. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028
[TBL] [Abstract][Full Text] [Related]
44. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [
Hardiansyah D; Yousefzadeh-Nowshahr E; Kind F; Beer AJ; Ruf J; Glatting G; Mix M
J Nucl Med; 2024 Apr; 65(4):566-572. PubMed ID: 38423787
[TBL] [Abstract][Full Text] [Related]
45. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
46. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
47. Repeated
Rathke H; Giesel FL; Flechsig P; Kopka K; Mier W; Hohenfellner M; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Mar; 59(3):459-465. PubMed ID: 28798031
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of
Siebinga H; Privé BM; Peters SMB; Nagarajah J; Dorlo TPC; Huitema ADR; de Wit-van der Veen BJ; Hendrikx JJMA
CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1060-1071. PubMed ID: 36760133
[TBL] [Abstract][Full Text] [Related]
49. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.
Kabasakal L; Toklu T; Yeyin N; Demirci E; Abuqbeitah M; Ocak M; Aygün A; Karayel E; Pehlivanoğlu H; Alan Selçuk N
Mol Imaging Radionucl Ther; 2017 Jun; 26(2):62-68. PubMed ID: 28613198
[TBL] [Abstract][Full Text] [Related]
50. A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After
Dewaraja YK; Mirando DM; Peterson AB; Niedbala J; Millet JD; Mikell JK; Frey KA; Wong KK; Wilderman SJ; Nelson AS
J Nucl Med; 2022 Nov; 63(11):1665-1672. PubMed ID: 35422445
[TBL] [Abstract][Full Text] [Related]
51. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
52. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
[TBL] [Abstract][Full Text] [Related]
53. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study.
Privé BM; Peters SMB; Muselaers CHJ; van Oort IM; Janssen MJR; Sedelaar JPM; Konijnenberg MW; Zámecnik P; Uijen MJM; Schilham MGM; Eek A; Scheenen TWJ; Verzijlbergen JF; Gerritsen WR; Mehra N; Kerkmeijer LGW; Smeenk RJ; Somford DM; van Basten JA; Heskamp S; Barentsz JO; Gotthardt M; Witjes JA; Nagarajah J
Clin Cancer Res; 2021 Jul; 27(13):3595-3601. PubMed ID: 33883176
[TBL] [Abstract][Full Text] [Related]
54. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
[TBL] [Abstract][Full Text] [Related]
55. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
56. Radioligand therapy using [
Seifert R; Kessel K; Schlack K; Weckesser M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2020 Aug; 47(9):2106-2112. PubMed ID: 32062682
[TBL] [Abstract][Full Text] [Related]
57. Prediction of response and survival after standardized treatment with 7400 MBq
Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131
[TBL] [Abstract][Full Text] [Related]
58. Nomograms to predict outcomes after
Gafita A; Calais J; Grogan TR; Hadaschik B; Wang H; Weber M; Sandhu S; Kratochwil C; Esfandiari R; Tauber R; Zeldin A; Rathke H; Armstrong WR; Robertson A; Thin P; D'Alessandria C; Rettig MB; Delpassand ES; Haberkorn U; Elashoff D; Herrmann K; Czernin J; Hofman MS; Fendler WP; Eiber M
Lancet Oncol; 2021 Aug; 22(8):1115-1125. PubMed ID: 34246328
[TBL] [Abstract][Full Text] [Related]
59. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
60. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
